Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Milva Orquidea Bal
Efficacy, Safety and Population Pharmacokinetics of Sapropterin in PKU Patients <4 Years: Results From the SPARK Open-Label, Multicentre, Randomized Phase IIIb Trial
Orphanet Journal of Rare Diseases
Medicine
Genetics
Pharmacology
Related publications
Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial
SKIN The Journal of Cutaneous Medicine
Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study
Clinical Therapeutics
Pharmacology
Single-Dose Pharmacokinetics of Co-Crystal of Tramadol-Celecoxib: Results of a 4-Way Randomized Open-Label Phase I Clinical Trial in Healthy Subjects
British Journal of Clinical Pharmacology
Pharmacology
Efficacy, Safety and Pharmacokinetics of Subcutaneous Azacitidine in Chinese Patients With Higher Risk Myelodysplastic Syndromes: Results From a Multicenter, Single-Arm, Open-Label Phase 2 Study
Asia-Pacific Journal of Clinical Oncology
Medicine
Oncology
Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study
Journal of the American Academy of Dermatology
Dermatology
A Multicentre Open-Label Safety and Efficacy Study of Tetrodotoxin for Cancer Pain
Current Oncology
Oncology
Safety and Efficacy of Intrarenal Arterial Autologous CD34+ Cell Transfusion in Patients With Chronic Kidney Disease: A Randomized, Open-Label, Controlled Phase II Clinical Trial
Stem cells translational medicine
Medicine
Developmental Biology
Cell Biology
Safety and Efficacy of Pasireotide in Dumping Syndrome-Results From a Phase 2, Multicentre Study
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Trial Design of Phase IIIb, Open-Label, Single Arm Study to Evaluate Efficacy and Safety of Pasireotide LAR in Patients With Inadequately-Controlled Acromegaly Despite Treatment With First-Generation Somatostatin Analogues
Endocrine Abstracts